Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study - Scorecard - MDSpire
Advertisement
Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study
Clinical Scorecard: Evaluating the Potential for Hepatitis B Virus Reactivation in COVID-19 Patients Undergoing Corticosteroid Therapy: A Retrospective Observational Study
At a Glance
Category
Detail
Condition
Hepatitis B Virus Reactivation in COVID-19 Patients
Key Mechanisms
Systemic corticosteroids may reactivate latent HBV infections.
Target Population
Hospitalized adult patients with COVID-19 requiring corticosteroids.
Care Setting
University Medical Centre Ljubljana, Slovenia.
Key Highlights
Corticosteroids recommended for COVID-19 may increase HBV reactivation risk.
Risk of HBV reactivation is substantial in HBsAg positive patients on high-dose corticosteroids.
EASL recommends antiviral therapy for patients with chronic or resolved HBV undergoing corticosteroid treatment.
Guideline-Based Recommendations
Diagnosis
Screen for anti-HBc in all patients undergoing corticosteroid therapy for COVID-19.
Reflex HBsAg testing in anti-HBc positive cases.
Management
Consider antiviral prophylaxis for individuals with detectable HBV DNA.
Monitoring & Follow-up
Assess transaminases and HBV DNA levels in anti-HBc positive patients.
Risks
Increased risk of HBV reactivation with high-dose corticosteroids (>20 mg prednisone daily).
Patient & Prescribing Data
Adult patients hospitalized with COVID-19.
Corticosteroids used include dexamethasone 6 mg daily or equivalent.
Clinical Best Practices
Adhere to EASL guidelines for HBV management in corticosteroid-treated COVID-19 patients.
Monitor HBV status in patients receiving systemic corticosteroids.
